Latest stories on CRSP
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool54 · neutralanalyst
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool53 · neutralanalyst
Why CRISPR Therapeutics Stock Rocked the Market Last Month
Yahoo Top67 · bullishgeneral
Why CRISPR Therapeutics Stock Rocked the Market Last Month
The Motley Fool67 · bullishgeneral
Where Will CRISPR Therapeutics Stock Be in 5 Years?
Yahoo Top67 · bullishgeneral
Where Will CRISPR Therapeutics Stock Be in 5 Years?
The Motley Fool67 · bullishgeneral
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire56 · neutralgeneral
Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321
The Fly56 · neutralanalyst
CRISPR Therapeutics: CASGEVY Validates The Platform, Strengthening The Acquisition Case
Seeking Alpha67 · bullishanalyst
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
Yahoo Finance63 · neutralgeneral
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
The Motley Fool63 · neutralgeneral
Investors Shrug Off Good News for Heart Patients From New Meds
Barron's42 · neutralproduct/pr
H.C. Wainwright reiterates CRISPR Therapeutics stock rating at buy
Investing.com Analyst Ratings61 · neutralanalyst
Citizens reiterates CRISPR Therapeutics stock rating on gene therapy data
Investing.com Analyst Ratings56 · neutralanalyst
Lateral Flow Assay Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035
GlobeNewswire50 · neutralgeneral
CRSP Stock Slips 3% Despite ‘Encouraging’ CTX310 Data — Morgan Stanley Says Investor Focus Is Further Ahead
Stocktwits News48 · neutralproduct/pr
Crispr Therapeutics durability data ‘encouraging,’ says Morgan Stanley
The Fly63 · neutralanalyst
Citizens reaffirms CRISPR Therapeutics stock rating on gene therapy data
Investing.com Analyst Ratings56 · neutralanalyst
CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?
The Motley Fool42 · neutralgeneral
Crispr Therapeutics Price Target Raised To 55 From 48 At Goldman Sachs Thefly News 2
The Fly61 · neutralanalyst
Crispr Therapeutics Price Target Lowered To 82 From 83 At Bofa
The Fly34 · bearishanalyst
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
The Fly63 · neutralanalyst
CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310
Seeking Alpha73 · bullishproduct/pr